<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03804658</url>
  </required_header>
  <id_info>
    <org_study_id>CG18308A</org_study_id>
    <nct_id>NCT03804658</nct_id>
  </id_info>
  <brief_title>The Factors Affecting the Achievement of Glucose Monitor in the Patients on Diabetes</brief_title>
  <official_title>The Effects of Glucose Monitor on Patients With Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taichung Veterans General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taichung Veterans General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the effect of glucose monitors on glucose control and cardiovascular risks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will enroll patients with diabetes. The answered questionnaire and blood
      samples will be collected at baseline. After change the methods or frequency of glucose
      monitor, the blood samples will be collected again. The investigators will analyze the
      factors which may affect the glucose control after changes in methods of glucose monitor.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 13, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Months</target_duration>
  <primary_outcome>
    <measure>Glucose variability</measure>
    <time_frame>3 months</time_frame>
    <description>Data from continue glucose monitor system</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>brain-derived neurotrophic factor</measure>
    <time_frame>3 months</time_frame>
    <description>Biomarker of cognition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Orexin</measure>
    <time_frame>3 months</time_frame>
    <description>Biomarker of cognition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renalase</measure>
    <time_frame>3 months</time_frame>
    <description>Biomarker of cognition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular endothelial cell adhesion molecule 1</measure>
    <time_frame>3 months</time_frame>
    <description>Biomarker for inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Literacy</measure>
    <time_frame>3 months</time_frame>
    <description>Questionnaire of health</description>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Glucose Variability</condition>
  <condition>Cognitive Decline</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Continue glucose monitor system</intervention_name>
    <description>The cardiovascular risks and data from continue glucose monitor system</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum, Plasma and urine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adults with diabetes both in outpatient and inpatient
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults with diabetes

        Exclusion Criteria:

          -  Incooperative patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>I-Te Lee, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taichung Veterans General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>I-Te Lee, MD,PhD</last_name>
    <phone>+886-4-23592525</phone>
    <phone_ext>4006</phone_ext>
    <email>itlee@vghtc.gov.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Division of Endocrinology and Metabolism in Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>407</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>I-Te Lee, MD</last_name>
      <phone>886-4-23741340</phone>
      <email>itlee@vghtc.gov.tw</email>
    </contact>
    <investigator>
      <last_name>I-Te Lee, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>January 11, 2019</study_first_submitted>
  <study_first_submitted_qc>January 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 15, 2019</study_first_posted>
  <last_update_submitted>February 5, 2019</last_update_submitted>
  <last_update_submitted_qc>February 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Brain-derived neurotrophic factor</keyword>
  <keyword>Vascular cell adhesion molecule 1</keyword>
  <keyword>Renalase</keyword>
  <keyword>Orexin</keyword>
  <keyword>Continue glucose monitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Not to share individual participant data</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

